Researchers at the Texas A&M Health Institute of Biosciences and Technology have developed a molecular switch called CODS (caffeine-operated dissociation system) that uses caffeine to control engineered cells. Published in the Journal of the American Chemical Society in 2026, the system allows scientists to trigger or pause gene-editing activity and immune cell responses on demand.
How does the caffeine-operated switch work?
The CODS platform acts as a molecular “clasp” within living cells. According to the research team, led by Yubin Zhou, MD, PhD, the system uses AI-guided protein design to create a synthetic binder that holds protein modules together. In the absence of caffeine, the clasp remains closed. When a small dose of caffeine—such as that found in coffee, soda, or chocolate—is introduced, the proteins separate, effectively acting as a “brake” or “pause button” for cellular activity.
Unlike previous technologies that used caffeine to pull engineered proteins together, CODS is designed to pull them apart. This distinction is critical for medical applications where clinicians may need to quiet or reset therapy-induced responses.
Why is this important for cancer treatment?
The most significant potential application for CODS is in CAR T-cell therapy. While these immune cells have shown success in treating blood cancers, they can sometimes become dangerously overactive. According to the Texas A&M research, CODS provides a potential safety mechanism. By using a split CAR system that remains active only when caffeine is absent, clinicians could theoretically use a dose of caffeine to temporarily reduce CAR T-cell activity, preventing serious side effects without destroying the therapeutic cells entirely.
How did AI enable this medical breakthrough?
Designing these synthetic proteins required significant computational power. The team utilized the Texas A&M High Performance Research Computing (HPRC) service to run complex AI-driven workflows. According to Yubin Zhou, this high-performance computing was essential to move from conceptual designs to a functional switch that responds to low concentrations of caffeine within minutes. This marks a departure from nature-based protein design, allowing scientists to create “mini proteins” with specific, programmable behaviors.
Frequently Asked Questions
- Is drinking coffee a medical treatment? No. As Yubin Zhou noted, caffeine is not a cancer treatment; it serves as a safe, familiar signal to communicate with engineered cells.
- Can the process be reversed? Yes. The researchers found the system could be reversed repeatedly by adding or removing caffeine.
- Is this ready for clinical use? Not yet. The system requires further testing in therapeutic cells and animal models before it can be considered for human clinical settings.
Interested in the intersection of AI and biotechnology? Subscribe to our research newsletter or leave a comment below to discuss how synthetic biology might change the way we approach chronic disease.
Keep reading
- Toddler’s Metastatic Cancer Cured by Experimental Therapy
- How Reading Protects Your Brain for Life: From Bedtime Stories to Book Clubs
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)